Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2020
BCD-089 is the original therapeutic monoclonal antibody binding the alpha subunit of the IL-6 receptor. The aim of the study is to demonstrate the efficacy and safety of BCD-089 in combination with methotrexate in patients with active rheumatoid arthritis resistant to monotherapy with methotrexate.
Epistemonikos ID: 01f6bd3d92dde26e8366b5c0db9bb808f96166c4
First added on: Mar 23, 2022